resTORbio, Inc. (NASDAQ:TORC) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $29.25 for the company and are forecasting that the company will post ($1.03) EPS for the current quarter, according to Zacks. Zacks has also given resTORbio an industry rank of 199 out of 265 based on the ratings given to its competitors.
A number of analysts recently commented on TORC shares. Wedbush started coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $30.00 price objective for the company. Leerink Swann started coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $36.00 price objective for the company. Bank of America started coverage on resTORbio in a research report on Tuesday, February 20th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Evercore ISI started coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $28.00 price objective for the company.
In other resTORbio news, major shareholder Puretech Health Llc purchased 233,333 shares of the stock in a transaction on Tuesday, January 30th. The stock was bought at an average price of $15.00 per share, for a total transaction of $3,499,995.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc purchased 533,333 shares of the stock in a transaction on Tuesday, January 30th. The stock was acquired at an average price of $15.00 per share, with a total value of $7,999,995.00. The disclosure for this purchase can be found here.
WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2018/03/14/brokerages-anticipate-restorbio-inc-torc-to-post-1-03-earnings-per-share.html.
resTORbio Company Profile
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.